Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of **metoclopramide** and **mosapride**, both of which are gastrointestinal prokinetic agents used to enhance gastrointestinal motility. Metoclopramide is primarily a dopamine receptor antagonist, while mosapride is a selective 5-HT4 receptor agonist. This combination would theoretically be used to enhance gastric emptying and treat conditions with impaired gastrointestinal motility, such as gastroparesis, functional dyspepsia, or ileus. Both drugs improve gastrointestinal transit, but via different mechanisms: metoclopramide blocks dopamine D2 receptors enhancing acetylcholine release in the GI tract, while mosapride stimulates serotonin 5-HT4 receptors, further promoting acetylcholine release and motility[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on metoclopramide + mosapride.